Venus Remedies obtains Marketing Authorizations for range of essential oncology drugs in Ukraine

09 Mar 2024 Evaluate

Venus Remedies has successfully obtained Marketing Authorizations (MAs) for a range of essential oncology drugs in Ukraine (Asia CIS). This includes PACLITAXEL in various strengths of 100mg/16.7mL, 260mg/43.3mL, 300mg/50mL and 30mg/5mL, OXALIPLATIN in concentrations of 50mg/10mL and 100mg/20mL and lRINOTECAN in formulations of 100mg/5mL and 40mg/2mL. These approvals mark significant progress for Venus Remedies in expanding its market presence and providing access to critical medications for cancer patients in the region. The company remains committed to its mission of delivering high quality pharmaceuticals to improve healthcare outcomes globally.

Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.


Venus Remedies Share Price

325.55 -2.75 (-0.84%)
29-Apr-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1521.95
Dr. Reddys Lab 6279.95
Cipla 1407.55
Zydus Lifesciences 963.50
Lupin 1640.30
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.